Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas

Journal of Immunology

Volumn 160, Issue 1, 1998, Pages 328-333

  Gnjatic, Sacha ^a,c   Cai, Zhenzi ^b   Viguier, Mireille ^a   Chouaib, Salem ^b   Guillet, Jean Gérard ^a   Choppin, Jeannine ^a,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Université Paris Descartes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA A2 ANTIGEN; PROTEIN P53;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MELANOMA; NORMAL HUMAN; PRIORITY JOURNAL;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; MELANOMA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031905632     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Browning, M. J., and W. F. Bodmer. 1992. MHC antigens and cancer: implications for T-cell surveillance. Curr. Opin. Oncol. 4:613.
2. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
3. Robbins, P. F., and Y. Kawakami. 1996. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 8:628.
4. Disis, M. L., and M. A. Cheever. 1996. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. 8:637.
5. Kawakami, Y., and S. A. Rosenberg. 1996. T-cell recognition of self peptides as tumor rejection antigens. Immunol. Res. 15:179.
6. Crawford, L. V., D. C. Pim, and R. D. Bulbrook. 1982. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int. J. Cancer 30:403.
7. Soussi, T. 1996. The humoral response to the tumor-suppressor gene-product p53 in human cancer: implications for diagnosis and therapy. Immunol. Today 17: 354.
8. Tilkin, A.-F., R. Lubin, T. Soussi, V. Lazar, N. Janin, M.-C. Mathieu, I. Lefrère, C. Carlu, M. Roy, M. Kayibanda, D. Bellet, J.-G. Guillet, and B. Bressac-de Paillerets. 1995. Primary proliferate T cell response to wild-type p53 protein in patients with breast cancer. Eur. J. Immunol. 25:1765.
9. Soong, R., P. D. Robbins, B. R. Dix, F. Grieu, B. Lim, S. Knowles, K. E. Williams, G. R. Turbett, A. K. House, and B. J. Iacopetta. 1996. Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum. Pathol. 27:1050.
10. Hollstein, M., B. Shomer, M. Greenblatt, T. Soussi, E. Hovig, R. Montesano, and C. C. Harris. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 24:141.
11. + T cells. Proc. Natl. Acad. Sci. USA 91:3171.
12. + cytotoxic T-cells. Cancer Res. 53:3257.
13. Lacabanne, V., M. Viguier, J.-G. Guillet, and J. Choppin. 1996. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells. Eur. J. Immunol. 26:2635.
14. Mayordomo, J. I., D. J. Loftus, H. Sakamoto, C. M. De Cesare, P. M. Appasamy, M. T. Lotze, W. J. Storkus, E. Appella, and A. B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357.
15. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine and L. A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92:11993.
16. Röpke, M., J. Hald, P. Guldberg, J. Zeuthen, L. Nørgaard, L. Fugger, A. Svejgaard, S. Van Der Burg, H. W. Nijman, C. J. M. Melief, and M. H. Claesson. 1996. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA 93:14704.
17. Lassam, N. J., L. From, and H. J. Kahn. 1993. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res. 53:2235.
18. Takahashi, K., H. Sumimoto, K. Suzuki, and T. Ono. 1993. Protein synthesis-dependent cytoplasmic translocation of p53 protein after serum stimulation of growth-arrested MCF-7 cells. Mol. Carcinogen. 8:58.
19. Balcer-Kubiczek, E. K., J. Yin, K. Lin, G. H. Harrison, J. M. Abraham, and S. J. Meltzer. 1995. p53 mutational status and survival of human breast cancer MCF-7 cell variants after exposure to X rays or fission neutrons. Radiat. Res. 142:256.
20. Cerny, A., P. Fowler, M. A. Brothers, M. Houghton, H. J. Schlicht, and F. V. Chisari. 1995. Induction in vitro of a primary human antiviral cytotoxic T cell response. Eur. J. Immunol. 25:627.
21. Gnjatic, S., B. Bressac-de Paillerets, J.-G. Guillet, and J. Choppin. 1995. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur. J. Immunol. 25:1638.
22. Houbiers, J. G. A., H. W. Nijman, S. H. van der Burg, J. W. Drijfhout, P. Kenemans, C. J. H. van der Velde, A. Brand, F. Momburg, W. M. Kast, and C. J. M. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23:2072.
23. Nijman, H. W., J. G. A. Houbiers, S. H. van der Burg, M. P. M. Vierboom, P. Kenemans, W. M. Kast, and C. J. M. Mehef. 1993. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protem, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother. 14:121.
24. Röpke, M., M. Regner, and M. H. Claesson. 1995. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol. 42:98.
25. Theobald, M., J. Biggs, J. Hernández, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:833.
26. Bargonetti, J., J. J. Manfredi, X. Chen, D. R. Marshak, and C. Prives. 1993. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev. 7:2565.
27. Selkirk, J. K., B. A. Merrick, B. L. Stackhouse, and C. He. 1994. Multiple p53 protein isoforms and formation of oligomeric complexes with heat shock proteins Hsp70 and Hsp90 in the human mammary tumor, T47D, cell line. Appl. Theor. Electrophor. 4:11.
28. Fuller, K. J., R. D. Issels, D. O. Slosman, J. G. Guillet, T. Soussi, and B. S. Polla. 1994. Cancer and the heat shock response. Eur. J. Cancer 30A:1884.
29. Rivoltini, L., K. C. Barrachini, V. Viggiano, Y. Kawakami, A. Smith, A. Mixon, N. P. Restifo, S. L. Topalian, T. B. Simonis, S. A. Rosenberg, and F. M. Marincola. 1995. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 55:3149.
30. Geldhof, A. B., T. Vandendriessche, G. Opdenakker, and P. Debaetselier. 1996. Introduction of the interferon gamma gene into mouse T lymphoma cells with low MHC class I-expression results in selective induction of H-2D(k) and concomitant enhanced metastasis. Cancer Immunol. Immunother. 42:329.
31. Dahl, A. M., P. C. Beverley, and H. J. Stauss. 1996. A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein. J. Immunol. 157:239.
32. Linehan, D. C., P. S. Goedegebuure, G. E. Peoples, S. O. Roger, and T. J. Eberlein. 1995. Tumor-specific and HLA-A2-restricted cvtolysis by tumor-associated lymphocytes in human metastatic breast cancer. J. Immnnol. 155: 4486.